<p><em>州政府资助的筛查倡议凸显了公共部门对创新癌症检测工具的日益支持</em></p>
<p>马里兰州盖瑟斯堡，2026 年 3 月 27 日（GLOBE NEWSWIRE）-- 20/20 BioLabs, Inc.（纳斯达克：AIDX），一家在基于人工智能的实验室血液检测领域早期进入市场的公司，专注于癌症和慢性疾病的早期检测与预防，今天宣布，马里兰州 18 个消防部门已被通知将共同获得超过 520,000 美元的资金，用于采购和实施公司的专利_OneTest_™多癌症早期检测（MCED）血液检测。</p>
<p>这笔资金来自州政府的 <strong>专业和志愿消防员创新癌症筛查技术补助计划</strong>，由马里兰州卫生部（MDH）管理。预计对这些消防员的检测人数将超过 1,400 人，计划于今年 4 月或 5 月进行，这代表了通过同一计划资助的_OneTest_ MCED 数量比去年增加了约 225%。</p>
<p>“索尔兹伯里消防局对 OneTest 癌症筛查产品非常满意，” 索尔兹伯里消防局副局长 Truitt 表示，该局已被通知将再次获得州政府的资金。“在过去三年中，这些检测使我们能够进行近 300 次筛查。通过我们的移动综合健康团队和急救人员进行简单的抽血，我们的成员能够及时获得结果，从而进行必要的后续护理。整个过程简单高效，我们对产品和提供的服务感到非常满意。”</p>
<p>马里兰州是几个新设立专门补偿或补助资金的州之一，以便其消防员能够获得 MCED 检测，预计在未来 24 个月内将有更多州创建类似计划。根据国家职业安全与健康研究所及其他研究机构的研究，消防员面临多种癌症类型的职业暴露风险和死亡率较高。</p>
<p>“作为一名曾经的志愿消防员，为这个面临更高癌症暴露风险的社区服务让我感到特别欣慰，” 20/20 BioLabs 首席执行官 Jonathan Cohen 表示。“我们很自豪能够通过这些项目支持马里兰州的消防部门。我们从这些检测中获得的数据，加上我们对全国至少 20,000 名其他消防员的检测，可以为即将与 FDA 和 CMS 的接触提供真实的证据，” Cohen 说道。</p>
<p>上个月，国会通过了一项立法并签署成为法律，为 2028 年开始的医疗保险覆盖 MCED 建立了一条途径。公司计划为其专利的_OneTest_癌症检测申请医疗保险覆盖，并相信其将已知蛋白肿瘤标志物水平与机器学习人工智能结合的专利方法在成本、对许多早期癌症的更好检测率以及能够在家中、工作场所或零售地点进行无痛毛细血管血液采集等方面具有显著优势。</p>
<p><strong>关于 20/20 BioLabs</strong></p>
<p>20/20 BioLabs, Inc.（纳斯达克：AIDX）开发和商业化基于人工智能的实验室血液检测，用于癌症和慢性疾病的早期检测与预防。公司在 OneTest 品牌下提供两类实验室检测。_OneTest™ for Cancer_是一种多癌症早期检测（MCED）血液检测，而_OneTest for Longevity™_则测量炎症生物标志物，预计将在 2026 年上半年推出。OneTest 的经济实惠、准确、可及的检测可以方便地在家中使用新的上臂毛细血管采集设备，避免了疼痛的针头。检测在其位于马里兰州盖瑟斯堡的美国病理学家学院（CAP）认证、临床实验室改进修正案（CLIA）许可的实验室中进行。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告中的某些声明属于《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条所定义的 “前瞻性声明”。这些前瞻性声明涉及已知和未知的风险和不确定性，并基于公司对未来事件的当前预期和预测，这些事件可能影响其财务状况、经营结果、商业战略和财务需求。前瞻性声明可以通过 “可能”、“可以”、“将”、“应该”、“会”、“期望”、“计划”、“打算”、“预期”、“相信”、“估计”、“预测”、“潜在”、“项目”、“继续” 或这些术语的否定形式或其他类似表达来识别。实际结果可能与这些前瞻性声明所表达或暗示的结果有重大差异。多种因素可能导致实际结果与这些前瞻性声明中包含的结果有重大差异，包括但不限于公司在美国证券交易委员会（“SEC”）的文件中描述的风险，这些文件可在 SEC 网站 www.sec.gov 上获取，包括公司的 S-1 表格注册声明（修订版，文件编号 333-292125），以及我们不时提交或提供的其他报告。公司没有义务公开更新或修订任何前瞻性声明，以反映本公告日期后发生的事件或情况，或反映意外事件的发生，除非适用法律要求。尽管公司相信这些前瞻性声明中表达的期望是合理的，但无法保证未来结果，投资者应注意实际结果可能与预期结果有重大差异。</p>
<p><strong>投资者关系</strong></p>
<p>克里斯·泰森</p>
<p>MZ 集团</p>
<p>直线电话：949-491-8235</p>
<p>AIDX@mzgroup.us</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZM09UUTROeU0zTlRBMU1qZzFJekl6TURnNE9EZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZM09UUTROeU0zTlRBMU1qZzFJekl6TURnNE9EZz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGY2NTJmNjEtYTg1NS00MWNjLWFjOWMtYzk5OGE4NTk0NGIzLTEzMjA0MzgtMjAyNi0wMy0yNy1lbg==/tiny/20-20-Biolabs-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGY2NTJmNjEtYTg1NS00MWNjLWFjOWMtYzk5OGE4NTk0NGIzLTEzMjA0MzgtMjAyNi0wMy0yNy1lbg==/tiny/20-20-Biolabs-Inc-.png"/></p>

AIDX

<p>20/20 BioLabs, Inc. 宣布，18 个马里兰州消防部门将从马里兰州卫生部门获得超过 520,000 美元的资金，用于 OneTest™ 多癌症早期检测血液测试。这项资金是州政府倡议的一部分，旨在对超过 1,400 名消防员进行筛查，比去年增加了 225%。该倡议突显了对创新癌症检测工具日益增长的支持，尤其是针对癌症风险较高的消防员。该公司计划寻求 Medicare 对其测试的覆盖，这些测试利用人工智能，旨在提高检测率和成本效益</p>

<p><em>State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools</em></p>
<div class="lb-trans"><p><em>州政府资助的筛查倡议凸显了公共部门对创新癌症检测工具的日益支持</em></p>
</div><p>GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that 18 groups of Maryland fire departments have been notified that they will collectively be awarded over $520,000 from the Maryland Department of Health (MDH) to procure and administer the Company’s patented <em>OneTest</em> ™ multi-cancer early detection (MCED) blood test.</p>
<div class="lb-trans"><p>马里兰州盖瑟斯堡，2026 年 3 月 27 日（GLOBE NEWSWIRE）-- 20/20 BioLabs, Inc.（纳斯达克：AIDX），一家在基于人工智能的实验室血液检测领域早期进入市场的公司，专注于癌症和慢性疾病的早期检测与预防，今天宣布，马里兰州 18 个消防部门已被通知将共同获得超过 520,000 美元的资金，用于采购和实施公司的专利_OneTest_™多癌症早期检测（MCED）血液检测。</p>
</div><p>The funding is from the state’s <strong>Professional and Volunteer Firefighter Innovative Cancer Screening Technologies Grant Program</strong>, administered by MDH. The testing of these firefighters, estimated to exceed 1,400 individuals, is expected to take place in April or May of this year and represents a ~ 225% increase in the number of <em>OneTest</em> MCEDs funded through the same program last year.</p>
<div class="lb-trans"><p>这笔资金来自州政府的 <strong>专业和志愿消防员创新癌症筛查技术补助计划</strong>，由马里兰州卫生部（MDH）管理。预计对这些消防员的检测人数将超过 1,400 人，计划于今年 4 月或 5 月进行，这代表了通过同一计划资助的_OneTest_ MCED 数量比去年增加了约 225%。</p>
</div><p>“The Salisbury Fire Department has been very satisfied with the OneTest cancer screening products,” said Deputy Chief Truitt of the Salisbury MD Fire Department, which was notified that they will again receive funding from the state program. “Over the past three years, these tests have enabled us to carry out almost 300 screenings. With a simple blood draw conducted by our Mobile Integrated Health team and paramedics, our members receive timely results that allow them to pursue any necessary follow-up care. The process has been straightforward and efficient, and we are extremely pleased with both the product and the service provided.”</p>
<div class="lb-trans"><p>“索尔兹伯里消防局对 OneTest 癌症筛查产品非常满意，” 索尔兹伯里消防局副局长 Truitt 表示，该局已被通知将再次获得州政府的资金。“在过去三年中，这些检测使我们能够进行近 300 次筛查。通过我们的移动综合健康团队和急救人员进行简单的抽血，我们的成员能够及时获得结果，从而进行必要的后续护理。整个过程简单高效，我们对产品和提供的服务感到非常满意。”</p>
</div><p>Maryland is one of several states with newly created, dedicated reimbursement or grant funding for their firefighters to access MCED testing with many more states expected to create such over the next 24 months. Firefighters face higher occupational exposure risk and mortality rates for several different cancer types, according to studies from the National Institute of Occupational Safety and Health and other research groups.</p>
<div class="lb-trans"><p>马里兰州是几个新设立专门补偿或补助资金的州之一，以便其消防员能够获得 MCED 检测，预计在未来 24 个月内将有更多州创建类似计划。根据国家职业安全与健康研究所及其他研究机构的研究，消防员面临多种癌症类型的职业暴露风险和死亡率较高。</p>
</div><p>“As a former volunteer firefighter, servicing this community at a higher risk for cancer exposure is especially gratifying for me,” noted Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs. “We are proud to support Maryland fire departments through these programs. The data we glean from these tests, coupled with those from at least 20,000 other firefighters from throughout the country that we have tested, can provide real-world evidence to support upcoming engagements with the FDA and CMS,” said Cohen.</p>
<div class="lb-trans"><p>“作为一名曾经的志愿消防员，为这个面临更高癌症暴露风险的社区服务让我感到特别欣慰，” 20/20 BioLabs 首席执行官 Jonathan Cohen 表示。“我们很自豪能够通过这些项目支持马里兰州的消防部门。我们从这些检测中获得的数据，加上我们对全国至少 20,000 名其他消防员的检测，可以为即将与 FDA 和 CMS 的接触提供真实的证据，” Cohen 说道。</p>
</div><p>Last month, legislation was passed by Congress and signed into law, establishing a pathway for Medicare coverage of MCEDs beginning in 2028. The Company plans to seek Medicare coverage for its patented <em>OneTest</em> for Cancer, and believes that its patented approach of coupling the levels of well-established protein tumor markers with machine learning AI has considerable advantages over DNA based MCEDs including cost, better detection rates for many earlier stage cancers, and the ability to utilize pain-free capillary blood collection at home, workplaces, or retail locations.</p>
<div class="lb-trans"><p>上个月，国会通过了一项立法并签署成为法律，为 2028 年开始的医疗保险覆盖 MCED 建立了一条途径。公司计划为其专利的_OneTest_癌症检测申请医疗保险覆盖，并相信其将已知蛋白肿瘤标志物水平与机器学习人工智能结合的专利方法在成本、对许多早期癌症的更好检测率以及能够在家中、工作场所或零售地点进行无痛毛细血管血液采集等方面具有显著优势。</p>
</div><p><strong>About 20/20 BioLabs</strong></p>
<div class="lb-trans"><p><strong>关于 20/20 BioLabs</strong></p>
</div><p>20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. <em>OneTest™ for Cancer</em> is a multi-cancer early detection, or MCED, blood test, and <em>OneTest for Longevity™</em>, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper arm capillary collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD.</p>
<div class="lb-trans"><p>20/20 BioLabs, Inc.（纳斯达克：AIDX）开发和商业化基于人工智能的实验室血液检测，用于癌症和慢性疾病的早期检测与预防。公司在 OneTest 品牌下提供两类实验室检测。_OneTest™ for Cancer_是一种多癌症早期检测（MCED）血液检测，而_OneTest for Longevity™_则测量炎症生物标志物，预计将在 2026 年上半年推出。OneTest 的经济实惠、准确、可及的检测可以方便地在家中使用新的上臂毛细血管采集设备，避免了疼痛的针头。检测在其位于马里兰州盖瑟斯堡的美国病理学家学院（CAP）认证、临床实验室改进修正案（CLIA）许可的实验室中进行。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions. Actual results may differ materially from those expressed or implied by such forward-looking statements. A number of factors could cause actual results to differ materially from those contained in these forward-looking statements, including, but not limited to, the risks described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), available on the SEC’s website at www.sec.gov, including the Company’s Registration Statement on Form S-1, as amended (File No. 333-292125), as well as in our other reports filed or furnished from time to time with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law. Although the Company believes the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee future results, and investors are cautioned that actual outcomes may differ materially from those anticipated.</p>
<div class="lb-trans"><p>本公告中的某些声明属于《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条所定义的 “前瞻性声明”。这些前瞻性声明涉及已知和未知的风险和不确定性，并基于公司对未来事件的当前预期和预测，这些事件可能影响其财务状况、经营结果、商业战略和财务需求。前瞻性声明可以通过 “可能”、“可以”、“将”、“应该”、“会”、“期望”、“计划”、“打算”、“预期”、“相信”、“估计”、“预测”、“潜在”、“项目”、“继续” 或这些术语的否定形式或其他类似表达来识别。实际结果可能与这些前瞻性声明所表达或暗示的结果有重大差异。多种因素可能导致实际结果与这些前瞻性声明中包含的结果有重大差异，包括但不限于公司在美国证券交易委员会（“SEC”）的文件中描述的风险，这些文件可在 SEC 网站 www.sec.gov 上获取，包括公司的 S-1 表格注册声明（修订版，文件编号 333-292125），以及我们不时提交或提供的其他报告。公司没有义务公开更新或修订任何前瞻性声明，以反映本公告日期后发生的事件或情况，或反映意外事件的发生，除非适用法律要求。尽管公司相信这些前瞻性声明中表达的期望是合理的，但无法保证未来结果，投资者应注意实际结果可能与预期结果有重大差异。</p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p>Chris Tyson</p>
<div class="lb-trans"><p>克里斯·泰森</p>
</div><p>MZ Group</p>
<div class="lb-trans"><p>MZ 集团</p>
</div><p>Direct: 949-491-8235</p>
<div class="lb-trans"><p>直线电话：949-491-8235</p>
</div><p>AIDX@mzgroup.us</p>
<div class="lb-trans"><p>AIDX@mzgroup.us</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZM09UUTROeU0zTlRBMU1qZzFJekl6TURnNE9EZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY3OTQ4NyM3NTA1Mjg1IzIzMDg4ODg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGY2NTJmNjEtYTg1NS00MWNjLWFjOWMtYzk5OGE4NTk0NGIzLTEzMjA0MzgtMjAyNi0wMy0yNy1lbg==/tiny/20-20-Biolabs-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MGY2NTJmNjEtYTg1NS00MWNjLWFjOWMtYzk5OGE4NTk0NGIzLTEzMjA0MzgtMjAyNi0wMy0yNy1lbg==/tiny/20-20-Biolabs-Inc-.png"/></p>

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test | AIDX Stock News

马里兰州的消防部门获得了 52 万美元的资金，用于使用 20/20 Biolabs 的 OneTest™多癌症早期检测血液测试进行癌症筛查 | AIDX 股票新闻